• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Spyryx Biosciences presents data from preclinical studies of SPX-101

Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were presented in three posters at the North American Cystic Fibrosis Conference.

According to the company, nebulized SPX-101 “operating through a novel mechanism of action that promotes the intracellular internalization of epithelial sodium channels, SPX-101 reestablishes the pathway that naturally controls the concentration of these channels and facilitates appropriate fluid levels on the airway surface to restore mucociliary clearance.”

SPX-101 was also shown to be stable, and 28-day toxicology studies in rats and dogs showed no toxicity or adverse effects for doses of up to 19.6 mg/kg/day.

Spyryx Biosciences President and CEO John Taylor said, “We are excited to share these positive results with the community of researchers and physicians who are all dedicated to finding breakthrough treatments for cystic fibrosis. We believe that SPX-101 represents the first therapeutic opportunity to leverage a natural, biological mechanism that is important to the maintenance of normal mucus clearance, with the potential to provide meaningful clinical benefit to all CF patients, regardless of mutation.”

Chief Medical Officer Alistair Wheeler added, “These studies provide important data demonstrating low toxicity and supporting the proposed clinical doses, with no dose-limiting toxicity in the lung or systemically, and with no significant systemic bioavailability. We believe these non-clinical data, combined with the exciting results from the single-ascending dose portion of our Phase 1 safety study, and the pending data from the multiple-ascending dose portion of the Phase 1, supports our intention to move forward with early entry into the clinic in our Phase 2 clinical development plan.”

Read the Spyryx Biosciences press release.

Share

published on November 2, 2016

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews